Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, preliminary announcement of annual report 20024 Mar 2003
Genmab, Genmab Announces Year End 2002 Financial Results4 Mar 2003
Genmab, annual report 20024 Mar 2003
Genmab, section 29 announcement from Biotech Turnaround Fund B.V.25 Feb 2003
InvestorService: Genmab, Genmab to Present at the BIO CEO & Investor Conference 200325 Feb 2003
Genmab, Genmab Presents New HuMax-CD20 and HuMax-EGFr Pre-Clinical Data7 Feb 2003
Genmab, US FDA Approves Genmab’s IND to Investigate HuMax-IL15 to Treat Rheumatoid Arthritis29 Jan 2003
Genmab, US FDA Approves Genmab’s IND for HuMax-CD4 to Treat Lymphoma
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
27 Jan 2003
Genmab, Genmab Achieves First Milestone in Roche Antibody Collaboration9 Jan 2003
Genmab, GENMAB TO PRESENT AT JP MORGAN H&Q HEALTHCARE CONFERENCE 20036 Jan 2003
Genmab, Financial Calendar 200318 Dec 2002
Genmab, last day of trading of Genmab’s Co-Ownership Interests (COIS) at the Frankfurt Stock Exchange10 Dec 2002
  • Previous
  • 1
  • More pages
  • 149
  • 150
  • 151
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863